tickdelta
Sign in
Tables

Tables in the 10-Q of ELI LILLY & Co

34 tables with numbers, filed Oct 29, 2026. Each one downloads as an Excel file or a CSV (numbers are stored as numbers), with the filing's address in the last row. Only the layout is tidied (a "$" or ")" in a cell of its own is joined to its number); no value is changed. Open the filing on sec.gov ↗

← Filings of LLY

Table 1 after “Securities registered pursuant to Section 12(b) of the Exchange Act:”

Title of Each ClassTrading SymbolsName of Each Exchange On Which Registered
Common Stock (no par value)LLYNew York Stock Exchange
2.125% Notes due 2030LLY30New York Stock Exchange
0.625% Notes due 2031LLY31New York Stock Exchange
0.500% Notes due 2033LLY33New York Stock Exchange
6.77% Notes due 2036LLY36New York Stock Exchange
1.625% Notes due 2043LLY43New York Stock Exchange
1.700% Notes due 2049LLY49ANew York Stock Exchange

First 8 of 10 rows. The download has all of them.

Table 2 after “Table of Contents”

Page
PART I. Financial Information5
Item 1.Financial Statements5
Consolidated Condensed Statements of Operations5
Consolidated Condensed Statements of Comprehensive Income6
Consolidated Condensed Balance Sheets7
Consolidated Condensed Statements of Cash Flows8
Notes to Consolidated Condensed Financial Statements9

First 8 of 23 rows. The download has all of them.

Table 3 after “(Dollars and shares in millions, except per-share data)”

Three Months Ended September 30,Nine Months Ended September 30,
2026202520262025
Revenue$24,397$17,601$67,170$45,887
Costs, expenses, and other:
Cost of sales3,9333,00810,7787,680
Research and development4,2473,46611,5769,536
Marketing, selling, and administrative3,1252,7419,4897,963
Acquired in-process research and development4,1816567,5412,381

First 8 of 20 rows. The download has all of them.

Table 4 after “(Dollars in millions)”

Three Months Ended September 30,Nine Months Ended September 30,
2026202520262025
Net income$6,451$5,583$20,942$14,002
Other comprehensive income, net of tax1325102511,116
Comprehensive income$6,583$6,093$21,193$15,118

Table 5 after “(Dollars in millions)”

September 30, 2026December 31, 2025
Assets(Unaudited)
Current Assets
Cash and cash equivalents$4,885$7,268
Accounts receivable22,08917,760
Other receivables3,1422,395
Inventories18,19413,744
Prepaid expenses16,86214,315

First 8 of 41 rows. The download has all of them.

Table 6 after “(Dollars in millions)”

Nine Months Ended September 30,
20262025
Cash Flows from Operating Activities
Net income$20,942$14,002
Adjustments to Reconcile Net Income to Cash Flows from Operating Activities:
Depreciation and amortization1,5881,411
Change in deferred income taxes(1,098)(959)
Stock-based compensation expense562490

First 8 of 31 rows. The download has all of them.

Table 7 after “The following table summarizes our revenue recognized in our consolidated condensed statements of operations:”

Three Months Ended September 30,Nine Months Ended September 30,
2026202520262025
Net product revenue$22,650$16,331$62,506$42,658
Collaboration and other revenue1,7471,2704,6643,229
Revenue$24,397$17,601$67,170$45,887

Table 8 after “The following table summarizes revenue, including net product revenue and collaboration and other revenue, by product for the three months e”

Three Months Ended September 30,
20262025
U.S.Outside U.S.TotalU.S.Outside U.S.Total
Cardiometabolic Health:
Mounjaro$4,998$5,725$10,723$3,550$2,965$6,515
Zepbound(1)5,267865,3523,568203,588
Jardiance(2)7817961,578424535959
Trulicity6013029047073451,052

First 8 of 21 rows. The download has all of them.

Table 9 after “The following table summarizes revenue, including net product revenue and collaboration and other revenue, by product for the nine months en”

Nine Months Ended September 30,
20262025
U.S.Outside U.S.TotalU.S.Outside U.S.Total
Cardiometabolic Health:
Mounjaro$14,022$15,306$29,328$9,508$6,048$15,556
Zepbound(1)14,27316714,4409,254289,281
Jardiance(2)1,9092,0143,9241,1161,5472,663
Trulicity2,1099323,0422,2211,0183,239

First 8 of 21 rows. The download has all of them.

Table 10 after “The following table summarizes revenue by geographical area:”

Three Months Ended September 30,Nine Months Ended September 30,
2026202520262025
Revenue(1):
U.S.$15,136$11,300$41,668$30,604
Europe4,4593,49812,2198,461
China9475602,5821,477
Japan6485551,8471,478
Rest of world3,2061,6888,8543,867

First 8 of 9 rows. The download has all of them.

Table 11 after “The following table summarizes our revenue recognized:”

Three Months Ended September 30,Nine Months Ended September 30,
2026202520262025
Jardiance$1,578$959$3,924$2,663

Table 12 after “For the nine months ended September 30, 2026 and 2025, our significant acquisitions that were accounted for as business combinations were Ke”

KeloniaCentessaVentyx
Acquisition dateJune 25, 2026June 24, 2026March 4, 2026
Business descriptionIn vivo chimeric antigen receptor T-cell (CAR-T) therapiesOrexin receptor 2 agonists for sleep-wake disordersOral therapies for inflammatory-mediated diseases
Estimated fair value as of acquisition date:
Cash$46$233$120
Acquired in-process research and development (IPR&D)4,6956,058977
Goodwill(1)1,0521,655232
Deferred tax liabilities, net(822)(1,279)(150)

First 8 of 16 rows. The download has all of them.

Table 13 after “The following table summarizes our significant acquired IPR&D charges during 2026 and 2025:”

CounterpartyCompound, Therapy, or AssetAcquisition MonthPhase of Development(1)Acquired IPR&D Charge
AtaiBeckley Inc. (AtaiBeckley)BPL-003 (mebufotenin benzoate), synthetic form of 5-MeO-DMT for treatment-resistant depressionSeptember 2026Phase 2$2,610
Curevo Inc. (Curevo)Amezosvatein, adjuvanted subunit vaccine for the prevention of shinglesJuly 2026Phase 2954
Ajax Therapeutics, Inc. (Ajax)AJ1-11095, oral, Type II JAK2 inhibitor for the treatment of myelofibrosis and polycythemia veraJune 2026Phase 1909
Orna Therapeutics, Inc. (Orna)ORN-252, CD19 targeting in vivo CAR-T therapy designed to treat B cell-driven autoimmune diseasesMay 2026Phase 11,233
SiteOne Therapeutics, Inc.(SiteOne)STC-004, Nav1.8 inhibitor for the treatment of painJuly 2025Phase 1494
Scorpion Therapeutics, Inc. (Scorpion)STX-478, PI3Kα inhibitor for the treatment of breast cancer and other advanced solid tumorsMarch 2025Phase 11,412

Table 14 after “The following table summarizes components of inventories:”

September 30, 2026December 31, 2025
Finished products$2,998$1,931
Work in process10,6888,183
Raw materials and supplies4,4603,587
Total (approximates replacement cost)18,14613,701
Increase to last-in, first-out cost4843
Inventories$18,194$13,744

Table 15 after “The following table summarizes certain fair value information at September 30, 2026 and December 31, 2025 for investment assets measured at ”

Fair Value Measurements Using
Carrying AmountCostQuoted Prices in Active Markets for Identical Assets (Level 1)Significant Other Observable Inputs (Level 2)Significant Unobservable Inputs (Level 3)Fair Value
September 30, 2026
Cash equivalents(1)$1,336$1,336$1,336$—$—$1,336
Short-term investments:
Available-for-sale debt securities(2)$14$14$5$9$—$14
Other securities6060—204060
Short-term investments$74

First 8 of 28 rows. The download has all of them.

Table 16 after “Below are the details of our issuance of long-term debt in 2026. The cash proceeds were used for general corporate purposes, including the r”

Date of IssuanceAmountMaturityStated Interest Rate
May 2026$9,0002028-20664.150%-5.700%(1)

Table 17 after “The following table summarizes the carrying amount and fair value using Level 2 inputs for our long-term debt:”

September 30, 2026December 31, 2025
Carrying AmountFair ValueCarrying AmountFair Value
Long-term debt, including current portion$49,503$43,687$42,503$39,799

Table 18 after “The following table summarizes the fair value for our contingent consideration liabilities:”

September 30, 2026December 31, 2025
Other current liabilities$818$34
Other noncurrent liabilities2,070217

Table 19 after “The following table summarizes the aggregate outstanding notional amounts of our foreign currency forward contracts in U.S. dollar equivalen”

September 30, 2026December 31, 2025
PurchaseSellPurchaseSell
Designated as accounting hedges$5,712$—$67$—
Not designated as accounting hedges11,4387,96914,2819,264

Table 20 after “The following table summarizes the effects of significant hedging activity on our consolidated condensed financial statements:”

Three Months Ended September 30,Nine Months Ended September 30,
2026202520262025
Recognized in other–net, (income) expense:
Foreign currency forward contracts not designated as accounting hedges$163$170$13$(468)
Recognized in other comprehensive income (loss):
Foreign currency-denominated notes:
Designated as accounting hedges376168(683)
Foreign currency forward contracts:

First 8 of 9 rows. The download has all of them.

Table 21 after “The following table summarizes components of equity with significant changes during the three months ended September 30, 2026 and 2025:”

Common StockAdditional Paid-in CapitalRetained EarningsAccumulated Other Comprehensive Loss
SharesAmount
Balance at June 30, 2026941.5$588$7,117$31,893$(2,761)
Net income6,451
Other comprehensive income, net of tax132
Purchases of common stock(0.3)—(377)
Issuance of stock under employee stock plans, net——(8)
Stock-based compensation200

First 8 of 18 rows. The download has all of them.

Table 22 after “The following table summarizes components of equity with significant changes during the nine months ended September 30, 2026 and 2025:”

Common StockAdditional Paid-in CapitalRetained EarningsAccumulated Other Comprehensive Loss
SharesAmount
Balance at December 31, 2025944.8$590$7,346$24,470$(2,880)
Net income20,942
Other comprehensive income, net of tax251
Cash dividends declared per share: $3.46(3,088)
Purchases of common stock(4.7)(3)(4,361)
Issuance of stock under employee stock plans, net1.11(599)

First 8 of 20 rows. The download has all of them.

Table 23 after “The following table summarizes the activity related to each component of accumulated other comprehensive income (loss) during the three mont”

Foreign Currency Translation(1)Retirement Benefit PlansOtherAccumulated Other Comprehensive Loss
Balance at June 30, 2026$(1,055)$(1,957)$250$(2,761)
Other comprehensive income (loss)13213(13)132
Balance at September 30, 2026$(922)$(1,944)$237$(2,629)
Balance at June 30, 2025$(1,758)$(2,193)$235$(3,716)
Other comprehensive income (loss)4662023510
Balance at September 30, 2025$(1,292)$(2,173)$259$(3,206)

Table 24 after “The following table summarizes the activity related to each component of accumulated other comprehensive income (loss) during the nine month”

Foreign Currency Translation(1)Retirement Benefit PlansOtherAccumulated Other Comprehensive Loss
Balance at December 31, 2025$(1,149)$(1,987)$255$(2,880)
Other comprehensive income (loss)22643(18)251
Balance at September 30, 2026$(922)$(1,944)$237$(2,629)
Balance at December 31, 2024$(2,390)$(2,179)$246$(4,322)
Other comprehensive income (loss)1,0986121,116
Balance at September 30, 2025$(1,292)$(2,173)$259$(3,206)

Table 25 after “The following table summarizes information for our single reportable segment, including significant segment expenses:”

Three Months Ended September 30,Nine Months Ended September 30,
2026202520262025
Revenue$24,397$17,601$67,170$45,887
Less:
Cost of sales3,9333,00810,7787,680
Early-stage research and development(1)1,6631,2504,3793,396
Late-stage research and development(1)2,5842,2167,1976,140
Marketing, selling, and administrative3,1252,7419,4897,963

First 8 of 13 rows. The download has all of them.

Table 26 after “The following table summarizes certain financial information:”

Three Months Ended September 30,Percent ChangeNine Months Ended September 30,Percent Change
2026202520262025
Revenue$24,397$17,60139$67,170$45,88746
Net income6,4515,5831620,94214,00250
Earnings per share - diluted7.226.211623.4215.5651

Table 27 after “for the year ended December 31, 2025:”

CompoundDevelopment
Insulin efsitora alfa (Onswik)The FDA approved insulin efsitora alfa for type 2 diabetes.
The Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion recommending insulin efsitora alfa for the treatment of type 2 diabetes in the EU.
Orforglipron (Foundayo)The FDA approved orforglipron for obesity.
The CHMP issued a positive opinion recommending orforglipron for the treatment of obesity and of type 2 diabetes in the EU.
Submitted orforglipron for type 2 diabetes in the U.S. and Japan.
Tirzepatide (Mounjaro)The FDA approved tirzepatide to reduce cardiovascular risk in type 2 diabetes.
RetatrutideAnnounced that Phase 3 trials for retatrutide for obesity met their primary endpoints.

First 8 of 16 rows. The download has all of them.

Table 28 after “The following table summarizes our revenue activity by region:”

Three Months Ended September 30,Percent ChangeNine Months Ended September 30,Percent Change
2026202520262025
U.S.$15,136$11,30034$41,668$30,60436
Outside U.S.9,2616,3014725,50215,28367
Revenue$24,397$17,60139$67,170$45,88746

Table 29 after “The following are components of the change in revenue compared with the prior year:”

Three Months Ended September 30,Nine Months Ended September 30,
2026 vs. 20252026 vs. 2025
U.S.Outside U.S.ConsolidatedU.S.Outside U.S.Consolidated
Volume41%76%53%42%93%59%
Price(7)(29)(15)(5)(30)(14)
Foreign exchange rates————41
Percent change34%47%39%36%67%46%

Table 30 after “The following table summarizes our revenue, including net product revenue and collaboration and other revenue, by product for the three mont”

Three Months Ended September 30,Percent Change
20262025
U.S.Outside U.S.TotalTotal
Mounjaro$4,998$5,725$10,723$6,51565
Zepbound(1)5,267865,3523,58849
Jardiance(2)7817961,57895965
Verzenio8976141,5111,4703
Trulicity6013029041,052(14)

First 8 of 11 rows. The download has all of them.

Table 31 after “The following table summarizes our revenue, including net product revenue and collaboration and other revenue, by product for the nine month”

Nine Months Ended September 30,Percent Change
20262025
U.S.Outside U.S.TotalTotal
Mounjaro$14,022$15,306$29,328$15,55689
Zepbound(1)14,27316714,4409,28156
Verzenio2,4481,8384,2864,1184
Jardiance(2)1,9092,0143,9242,66347
Trulicity2,1099323,0423,239(6)

First 8 of 11 rows. The download has all of them.

Table 32 after “The following table summarizes our gross margin, costs, and expenses:”

Three Months Ended September 30,Percent ChangeNine Months Ended September 30,Percent Change
2026202520262025
Gross margin$20,464$14,59340$56,392$38,20748
Gross margin as a percent of revenue83.9%82.9%84.0%83.3%
Research and development$4,247$3,46623$11,576$9,53621
Marketing, selling, and administrative3,1252,741149,4897,96319
Acquired IPR&D4,181656NM7,5412,381NM
Asset impairment, restructuring, and other special charges303365(17)1,285400NM

First 8 of 10 rows. The download has all of them.

Table 33 after “The following table summarizes the activity related to repurchases of our equity securities during the three months ended September 30, 2026”

Total Number of Shares Purchased (in thousands)Average Price Paid per ShareTotal Number of Shares Purchased as Part of Publicly Announced Plans or Programs (in thousands)Approximate Dollar Value of Shares that May Yet Be Purchased Under the Plans or Programs (in millions)
July 2026197$1,168.21197$6,759
August 2026281,188.97286,726
September 2026951,161.39956,615
Total3201,167.99320

Table 34 after “The following documents are filed as a part of this Quarterly Report:”

ExhibitDescription
3.1Amended Articles of Incorporation, incorporated by reference to Exhibit 3.1 to the Company's Current Report on Form 8-K filed on May 4, 2022
3.2Bylaws, as amended, incorporated by reference to Exhibit 3.2 to the Company's Current Report on Form 8-K filed on May 4, 2022
31.1Rule 13a-14(a) Certification of David Ricks, Chair, President, and Chief Executive Officer*
31.2Rule 13a-14(a) Certification of Lucas Montarce, Executive Vice President and Chief Financial Officer*
32Section 1350 Certification*
101Interactive Data Files (embedded within the Inline XBRL document)*
104Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)*

First 8 of 9 rows. The download has all of them.

Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.